Apellis Pharmaceuticals
Price & Volume
Stats
See more52W Range | $24.34-$71.90 |
Market Cap | $3.6B |
Shares Short | 18M |
Financials
See moreRevenue (12 Mos) | $715.2M |
Revenue Growth (YoY) | 78.3% |
Gross Profit (12 Mos) | $297.9M |
Diluted EPS | -$2.03 |
News
See moreYahoo Finance • 5 days ago
Apellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)
Yahoo Finance • 7 months ago
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
Yahoo Finance • 8 months ago
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
Yahoo Finance • 11 months ago
30 Biggest Biotechnology Companies in the World
About
CEO | Dr. Cedric Francois M.D., Ph.D. |
CFO | Mr. Timothy E. Sullivan |
Address | 100 Fifth Avenue, Waltham, MA, United States, 02451 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 702 |
